Amgen AMGN

Robert A. Bradway has served as our director since 2011 and Chairman of the Board since 2013. Mr. Bradway has been our President since 2010 and Chief Executive Officer since 2012. From 2010 to 2012, Mr. Bradway served as our Chief Operating Officer. Mr. Bradway joined Amgen in 2006 as Vice President, Operations Strategy and served as Executive Vice President and Chief Financial Officer from 2007 to 2010. Prior to joining Amgen, he was a Managing Director at Morgan Stanley in London where, beginning in 2001, he had responsibility for the firm's banking department and corporate finance activities in Europe. Mr. Bradway has been a director of The Boeing Company, an aerospace company and manufacturer of commercial airplanes and defense, space and securities systems, since 2016, serving as the chair of the Governance and Public Policy Committee and a member of the Compensation Committee. Mr. Bradway has served on the board of trustees of USC since 2014. Mr. Bradway holds a bachelor's degree in biology from Amherst College and a master's degree in business administration from Harvard Business School. Qualifications Our Board concluded that Mr. Bradway should serve on our Board based on his thorough knowledge of all aspects of our business, combined with his leadership and management skills having previously served as our President and Chief Operating Officer and as our Chief Financial Officer, and board experience at large, highly regulated public companies.

Dr. James E. Bradner became Executive Vice President, Research and Development, in 2023 and also served as the Company's Chief Scientific Officer from 2023 to 2024. Prior to joining the Company, in 2023, Dr. Bradner was a clinician at the Dana-Farber Cancer Institute, a comprehensive cancer treatment and research institution, and a principal teaching affiliate at Harvard Medical School. From 2016 to 2022, Dr. Bradner served as President of the Novartis Institutes for BioMedical Research, the research and early development organizational unit of Novartis AG, where he was a member of the Executive Committee. Dr. Bradner previously served on the faculty at Harvard Medical School.

Mr. Murdo Gordon, age 59, became Executive Vice President, Global Commercial Operations, in 2018. Prior to joining the Company, Mr. Gordon was Chief Commercial Officer at Bristol-Myers Squibb Company (BMS), a pharmaceutical company, from 2016 to 2018. Mr. Gordon served as Head of Worldwide Markets at BMS from 2015 to 2016. Prior to this, Mr. Gordon served in a variety of leadership roles at BMS for more than 25 years.

Robert A. Eckert has served as our director since 2012 and our lead independent director since 2016. Mr. Eckert has been an Operating Partner at FFL Partners, LLC (formerly known as Friedman Fleischer & Lowe, LLP), a private equity firm, since 2014. Mr. Eckert was the Chief Executive Officer of Mattel, Inc., a toy design, manufacturing, and marketing company, from 2000 to 2011, and its chairman of the board from 2000 to 2012. He was President and Chief Executive Officer of Kraft Foods Inc., a consumer-packaged food and beverage company, from 1997 to 2000, Group Vice President from 1995 to 1997, President of the Oscar Mayer Foods Division from 1993 to 1995 and held various other senior executive and other positions from 1977 to 1992. Mr. Eckert has been a director of Levi Strauss & Co.,(1) a jeans and casual wear manufacturer, since 2010 and non-executive chair of the board since 2021, serving as the chair of the Nominating, Governance and Corporate Citizenship Committee and a member of the Compensation and Human Capital Committee. Mr. Eckert also has served as a director of Uber Technologies, Inc., a personal mobility, meal delivery and logistics technology platform, since 2020, serving as the chair of the Compensation Committee and a member of the Nominating and Governance Committee. Mr. Eckert served as a director of McDonald's Corporation, a company that franchises and operates McDonald's restaurants in the global restaurant industry, from 2003 to 2023. He also served as a director of Eyemart Express Holdings LLC, a privately held eyewear retailer and portfolio company of FFL Partners, LLC, from 2015 to 2025. Mr. Eckert has served on the Eller College national board of advisors at the University of Arizona since 2013. Mr. Eckert also served on the global advisory board of the Kellogg School of Management at Northwestern University from 1997 to 2025. Mr. Eckert received an undergraduate degree from the University of Arizona and a master's degree in business administration from the Kellogg School of Management at Northwestern University. Qualifications Our Board concluded that Mr. Eckert should serve on our Board because of Mr. Eckert's long-tenured and extensive experience as a chief executive officer, director, and board chair of large public companies, his broad international experience in marketing and business development, and his valuable governance and management leadership experience.

Ellen J. Kullman has served as our director since 2016. Ms. Kullman is chair of the board of Carbon, Inc., doing business as Carbon3D, Inc., a privately held 3D printing company, having held this position since 2022. Ms. Kullman served as President and Chief Executive Officer of Carbon, Inc. from 2019 to 2022 and has been a member of its board since 2016. She is the former President, chair and Chief Executive Officer of DuPont de Nemours, Inc., or DuPont, a science and technology-based company, where she served from 2009 to 2015. Ms. Kullman served as President of DuPont from 2008 to 2009. From 2006 to 2008, she served as Executive Vice President of DuPont. Prior to this, Ms. Kullman was Group Vice President, DuPont Safety and Protection. Ms. Kullman has been a director of Goldman Sachs Group, Inc., an investment banking firm, since 2016, chairing its Public Responsibilities Committee and serving on its Compensation and Corporate Governance and Nominating Committees. Ms. Kullman has been a director of Dell Technologies Inc., a technology company, since 2016, chairing its Nominating and Governance Committee and serving as lead independent director since 2023. Ms. Kullman served as a director of United Technologies Corporation, a technology products and services company, from 2011 until its merger with Raytheon Company in 2020, serving as lead director from 2018. Ms. Kullman served as a director of General Motors, from 2004 to 2008. Ms. Kullman has served on the board of trustees of Northwestern University since 2016 and is a trustee emerita of Tufts University School of Engineering, having served on its board of advisors since 2006. She served as chair of the U.S.-China Business Council from 2013 to 2015. Ms. Kullman has been a member of the Temasek Americas Advisory Panel of Temasek Holdings (Private) Limited, a privately held investment company based in Singapore, since 2016. Ms. Kullman received a bachelor of science in mechanical engineering degree from Tufts University and a master's degree from the Kellogg School of Management at Northwestern University. Qualifications Our Board concluded that Ms. Kullman should serve on our Board based on her lengthy global experience as chief executive officer and board chair at both public and private companies, her management and leadership skills, and her experience in scientific operations, all of which provide valuable insight into the operations of our Company.

Tyler Jacks has served as our director since 2012. Dr. Jacks joined the faculty of Massachusetts Institute of Technology, or MIT, in 1992 and is currently the David H. Koch Professor of Biology, a position he has held since 2007, and founding director of the David H. Koch Institute for Integrative Cancer Research, which brings together biologists and engineers to improve detection, diagnosis and treatment of cancer, serving as its director from 2007 to 2021. Since 2021, Dr. Jacks has served as President and director of Break Through Cancer, a foundation bringing together multidisciplinary cancer research teams selected from across five participating institutions.(1) Dr. Jacks was an investigator with the Howard Hughes Medical Institute, a nonprofit medical research organization, from 1994 to 2021. Dr. Jacks has been a director of Thermo Fisher Scientific, Inc., a life sciences supply company, since 2009, serving as the chair of its Science and Technology Committee and as a member of its Strategy and Finance Committee and its scientific advisory board. In 2006, he co-founded T2 Biosystems, Inc., a biotechnology company, and served on its scientific advisory board until 2013. Dr. Jacks served on the scientific advisory boards of SQZ Biotechnologies Company, a biotechnology company, from 2015 to 2023, and Aveo Pharmaceuticals Inc., a biopharmaceutical company, from 2001 to 2013. In 2015, Dr. Jacks founded Dragonfly Therapeutics, Inc., a privately held biopharmaceutical company, and serves as the chair of its scientific advisory board. Dr. Jacks served on the Harvard University Board of Overseers from 2019 to August 2025. In 2011, he was appointed to the National Cancer Advisory Board, which advises and assists the director of the National Cancer Institute with respect to the National Cancer Program, and served as chair until 2016. In 2016, Dr. Jacks was named to a blue ribbon panel of scientists and advisors established as a working group of the National Cancer Advisory Board and served as co-chair advising the Cancer MoonshotSM Task Force. Dr. Jacks was a director of MIT's Center for Cancer Research from 2001 to 2007 and received numerous awards including the Paul Marks Prize for Cancer Research and the American Association for Cancer Research Award for Outstanding Achievement. He was elected to the National Academy of Sciences as well as the National Academy of Medicine in 2009 and received the MIT Killian Faculty Achievement Award in 2015. Dr. Jacks received an undergraduate degree from Harvard University and his doctorate from the University of California, San Francisco. Qualifications Our Board concluded that Dr. Jacks should serve on our Board based on his extensive scientific expertise relevant to our industry, including his broad experience as a cancer researcher, pioneering uses of technology to study cancer-associated genes, and service on multiple scientific advisory boards and service to the National Cancer Advisory Board.

Mary E. Klotman has served as our director since 2024. Dr. Klotman has been Executive Vice President for Health Affairs of Duke University since 2023, Dean of the Duke University School of Medicine since 2017, and Chief Academic Officer of Duke Health since 2020. Dr. Klotman previously served as chair of the Department of Medicine at the Duke University School of Medicine from 2010 to 2017. She was the Irene and Dr. Arthur M. Fishberg Professor of Medicine at the Mount Sinai School of Medicine and served as chief of its Division of Infectious Diseases from 1997 to 2010. During this period, Dr. Klotman was also co-director of Mount Sinai's Global Health and Emerging Pathogens Institute, a program designed to translate basic science discoveries into clinical therapeutics for newly emerging and re-emerging infectious diseases. Dr. Klotman has been a director of Inventurus Knowledge Solutions Limited, doing business as IKS Health, a non-U.S. public company, since 2024, for which she has also served on its advisory board since 2022. Dr. Klotman was elected to the National Academy of Medicine in 2014 and the American Academy of Arts and Sciences in 2021. Dr. Klotman received both her undergraduate degree and her medical doctorate from Duke University. Qualifications Our Board concluded that Dr. Klotman should serve on our Board based on her broad medical and scientific background, including her expertise leading an important academic institution, her extensive scientific research, and important contributions as a clinician and physician-scientist.

Amy E. Miles has served as our director since 2020. Ms. Miles was the Chief Executive Officer and a director of Regal Entertainment Group, Inc., or Regal Entertainment, a leading theatre exhibition company, from 2009 to 2018, and its chair of the board from 2015 to 2018. From 2002 to 2009, Ms. Miles served as Executive Vice President, Chief Financial Officer and Treasurer of Regal Entertainment. Ms. Miles also served as Chief Executive Officer of Regal Cinemas, Inc., or Regal Cinemas, from 2009 to 2018, and its Executive Vice President, Chief Financial Officer and Treasurer from 2000 to 2009. Ms. Miles joined Regal Cinemas in 1999 as Senior Vice President of Finance. Previously, Ms. Miles was with Deloitte & Touche, LLP and PricewaterhouseCoopers LLP. Ms. Miles has been a director of The Gap, Inc., an apparel retail company, since 2020, chairing the Audit and Finance Committee and serving as a member of the Governance and Sustainability Committee. Ms. Miles has also been a director of Carrier Global Corporation since January 2025, serving as a member of the Audit and Governance Committees. Ms. Miles was a director of Norfolk Southern Corporation, a transportation company, from 2014 to 2024 and non-executive chair of the board from 2022 to 2024. Ms. Miles was a director of National CineMedia, Inc., a cinema advertising company, from 2011 to 2015. She was a director of Townsquare Media, Inc., a radio, digital media, entertainment, and digital marketing solutions company, from 2014 to 2016. Ms. Miles serves on the board of trustees of the Boys and Girls Club of the Tennessee Valley. Ms. Miles received an undergraduate degree from the University of Tennessee. Qualifications Our Board concluded that Ms. Miles should serve on our Board based on Ms. Miles' board and senior executive-level expertise, including her experience as chief executive officer and chief financial officer of a large public company and her extensive finance, accounting, and management expertise in marketing and strategic planning, and public board experience. Given her financial and leadership experience,

Michael V. Drake has served as our director since 2022. Dr. Drake is the retired President of the University of California, a system of 10 campuses, six academic health centers, and three nationally affiliated labs where he served from 2020 until his retirement in July 2025, and has served as Distinguished Professor of Ophthalmology at the University of California, San Francisco School of Medicine since August 2025. Dr. Drake previously served as President of The Ohio State University from 2014 to 2020. He was Chancellor and Distinguished Professor of Ophthalmology (School of Medicine) and Education (School of Education) of the University of California, Irvine, from 2005 to 2014, and served as Vice President for Health Affairs for the University of California system from 2000 to 2005. Prior to this, Dr. Drake was on the faculty of the University of California, San Francisco School of Medicine in various roles from 1979, and was the Steven P. Shearing Professor of Ophthalmology from 1998 to 2005 and Senior Associate Dean for Admissions and Extramural Academic Programs from 1998 to 2000. Dr. Drake received his undergraduate degree from Stanford University and his medical doctorate from the University of California, San Francisco. Qualifications Our Board concluded that Dr. Drake should serve on our Board based on his medical, healthcare, and scientific background and extensive management and leadership experience, including his more than two decades of leading and advancing two world-ranking academic systems where he demonstrated his expertise at managing complex organizations.

Effective September 1, 2026, Thomas Dittrich will serve as Executive Vice President and Chief Financial Officer of the Company. Mr. Dittrich will report to Robert A. Bradway, Chairman and Chief Executive Officer. Mr. Dittrich will initially be based in Rotkreuz, Switzerland and will be employed by Amgen (Europe) GmbH pursuant to an Employment Offer Agreement with Amgen (Europe) GmbH dated May 16, 2026. Mr. Dittrich is expected to relocate to Thousand Oaks, California in connection with his transition to Chief Financial Officer in September 2026.

Sean Bruich is senior vice president and Chief Technology Officer. Bruich is responsible for leading Amgen's efforts in accelerating the development and deployment of Artificial Intelligence (AI), and the advancement of data and data sciences to transform the company's science and operations through technology. In this role, he oversees AI and data, digital product management and engineering across the enterprise. He joined Amgen in 2024. Bruich has built a career advancing technical innovation in global insights and AI organizations through pivotal moments of industry transformation. Prior to joining Amgen, Bruich was vice president, Global Insights, Data Science, & Analytics at Nike. He and his teams led the development and deployment of machine learning algorithms across Nike's digital and retail experiences, co-led the design and launch of the company's first digital app storefronts, and led efforts to digitally power internal operations through data-driven measurement and forecasting. Before joining Nike, Bruich worked in Silicon Valley in data science innovation, product development, and commercialization at Facebook (now Meta) and Google. Bruich earned his Bachelor of Arts in Psychology and Biological Sciences from Stanford University.

Dr. Paul Burton, M.D., Ph.D., F.A.C.C., M.R.C.S., F.R.C.P., became Amgen's senior vice president and Chief Medical Officer in June 2023. As Chief Medical Officer, Dr. Burton leads the enterprise Medical Affairs organization, driving strategic collaboration across all therapeutic areas within R&D and Commercial, as well as with external key opinion leaders. He also oversees the Digital Medicine and Inclusive Global Health & Impact teams, which leverage data, technology, and community engagement to improve access to medical care, clinical trials, and treatments for populations that have historically faced barriers to healthcare. Dr. Burton's return to Amgen followed a tenure as CMO of Moderna Therapeutics, where he led global medical strategy as well as patient safety and pharmacovigilance from 2021 to 2023. Before that, he spent 16 years at Johnson & Johnson, where his last role was Chief Global Medical Affairs Officer. Dr. Burton has more than 20 years of biopharmaceutical industry experience, across all phases of drug discovery and development, spanning small and large molecules as well as mRNA therapeutics. He has also worked across multiple therapeutic areas, including oncology, cardiovascular and metabolic disease, and infectious diseases. Dr. Burton is a physician trained at University of London. He received post graduate training in cardiovascular surgery, and he holds a PhD in molecular and cellular biology from Imperial College, London. He is a Member of the Royal College of Surgeons, a Fellow of the American College of Cardiology, an elected Fellow of the Royal College of Physicians, and has published extensively in clinical and digital medicine.

Mr. Derek Miller, age 53, became Senior Vice President, Human Resources, in 2022. Mr. Miller joined the Company in 2003 and has held human resources leadership roles of increasing responsibility during his tenure. Mr. Miller's experience spans each of the Company's major business functions, including Vice President, Global Total Rewards, from 2020 to 2022 and Vice President, Human Resources, from 2018 to 2020.

Ms. Rachna Khosla, age 53, became Senior Vice President, Business Development, in 2021. Ms. Khosla joined the Company in 2013 and has held leadership roles in corporate development, licensing, and mergers and acquisitions, including as Vice President Business Development, from 2018 to 2021. Prior to joining the Company, Ms. Khosla was a Director at Lazard Ltd. (Lazard) responsible for healthcare mergers and acquisitions. Prior to Lazard, Ms. Khosla held various roles in investment banking (mergers and acquisitions) and corporate venture capital at Credit Suisse Group AG, Sanofi Aventis, Aventis Capital, J.P. Morgan Chase & Co., and Salomon Brothers, Inc.

Mr. Esteban Santos, age 58, became Executive Vice President, Operations, in 2016. Mr. Santos joined the Company in 2007 and has held a number of leadership roles at the Company in engineering, manufacturing, site operations and drug product, including Senior Vice President, Manufacturing, from 2013 to 2016. Prior to joining the Company, Mr. Santos served as Site General Manager of Johnson & Johnson's (J&J) Cordis operation in Puerto Rico. Prior to J&J, Mr. Santos held several management positions in GE's industrial and transportation businesses.

On August 1, 2023, the Board of Directors of Amgen Inc. appointed Matthew C. Busch to serve as the Company's Vice President, Finance and Chief Accounting Officer, effective August 14, 2023. Mr. Busch has served as the Company's Vice President, Finance since August 2021. From 2020 until August 2021, Mr. Busch served as Executive Director, Finance and, from 2017 until 2020, as Executive Director, Accounting. From 2004 until 2017, Mr. Busch progressed through various positions of increasing responsibility at the Company. He is a Certified Public Accountant and received his Masters of Accountancy degree and Bachelors of Science in Accounting from Brigham Young University.

Ms. Nancy A. Grygiel, age 58, became Senior Vice President and Chief Compliance Officer in 2020. Ms. Grygiel joined the Company in 2015 and has held leadership roles within the worldwide compliance and business ethics organization, including as Vice President, Compliance, from 2016 to 2020. Prior to joining Amgen, from 2011 to 2015, Ms. Grygiel served as Vice President, Compliance, Corporate & International, at Allergan, Inc. (Allergan). Prior to Allergan, Ms. Grygiel held several management positions at Mylan Pharmaceuticals, Inc.

Mr. Jonathan P. Graham, age 65, became Executive Vice President and General Counsel and Secretary in 2019. Mr. Graham joined the Company in 2015 to serve as Senior Vice President, General Counsel and Secretary. Prior to joining Amgen, from 2006 to 2015, Mr. Graham was Senior Vice President and General Counsel at Danaher Corporation. From 2004 to 2006, Mr. Graham was Vice President, Litigation and Legal Policy, at General Electric Company (GE). Prior to GE, Mr. Graham was a partner at Williams & Connolly LLP.